Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Smoking Cessation 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Cardiotoxicity 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Docetaxel 171Radiotherapy 144Magnetic Resonance Spectroscopy 142Leuprolide 112Prednisone 108enzalutamide 102Radiosurgery 101Abiraterone Acetate 94Androgen Antagonists 91Goserelin 83bicalutamide 81gallium 68 PSMA-11 70Surveys and Questionnaires 63apalutamide 57Specimen Handling 56acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 55Radiation 47Gonadotropin-Releasing Hormone 45Standard of Care 44Biopsy 44Brachytherapy 42Radiotherapy, Intensity-Modulated 40Blood Specimen Collection 40darolutamide 39abiraterone 39cabazitaxel 35Exercise 35Carboplatin 33Pluvicto 32Triptorelin Pamoate 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Prostatic Neoplasms × sulforaphane × Clear all
NCT04046653 2020-11-18

ADaPT

Quadram Institute Bioscience

Phase NA Completed
40 enrolled
Genitourinary

Prostatic Neoplasms

NCT01228084 2017-04-28

Sulforaphane in Treating Patients With Recurrent Prostate Cancer

OHSU Knight Cancer Institute

Phase 2 Completed
20 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡